CNBC's Meg Tirrell takes a look at Kaléo's naloxone, and how new technology of administering drugs are driving prices higher.
CNBC's Meg Tirrell reports on how first responders deal with emergency opioid overdose calls, and potential headwinds.
These are the stocks posting the largest moves after the bell.
David Nelson, Belpointe asset management, and Luke Timmerman, Timmerman Report, forecast 2017 trends in biotech and if the space is something to consider for your portfolio.
Ronny Gal, Sanford C. Bernstein analyst, shares his expectations on the biotech sector in 2017.
CNBC's Meg Tirrell takes a look at what investors can expect from the biotech and pharma sectors in the new year.
Beijia Ma, equity strategist at BofA Merrill Lynch, explains the nuances of the autonomous vehicle market, adding that sensor technology is crucial to its success.
Shares of Synergy Pharmaceuticals soar after positive drug trial results. CNBC's Morgan Brennan reports.
CNBC's Meg Tirrell looks at which stocks in the IBB of more than $1 billion market cap have the biggest potential upside.
CNBC's Meg Tirrell reports on how pharmaceutical companies, governments and nonprofits are better preparing for the next major infectious disease outbreak.
Nineteen U.S. senators send a letter to President-elect Donald Trump in an attempt to bring down drug prices. CNBC's Meg Tirrell reports.
Dec 20- Drugmaker Allergan Plc said on Tuesday it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP Inc, for $2.9 billion in cash, bringing the number of deals it has made this year to an even dozen. Allergan Chief Executive Brent Saunders has described the company's acquisition strategy as being one of "stepping stones."
Dec 20- Allergan Plc said it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP Inc, for $2.9 billion in cash. The acquisition will add LifeCell's dermal matrix products to Allergan's portfolio of medical aesthetics, breast implants and tissue expanders. Acellular dermal matrices are commonly used in breast reconstruction...
"Fast Money" trader David Seaburg pitches to the desk why to buy under-the-radar biotech stock AbbVie.
CNBC's Meg Tirrell speaks to new Biogen CEO Michel Vounatsos about the outlook of the company, Eli Lilly's experimental Alzheimer's drug and his expectations of the Trump administration.
Clovis Oncology shares jumped 15 percent Monday after the FDA approved Rubraca (rucaparib), the company's advanced ovarian cancer drug.
After a five-month search, Biogen names Michel Vounatsos its next CEO. CNBC's Meg Tirrell reports.
Shares of Gilead sink after-hours following a court order to pay Merck $2.5 billion in Hepatitis C royalties. CNBC's Meg Tirrell reports. The "Fast Money" traders weigh in.
Shares of Agios Pharmaceuticals are plunging on news that the company will discontinue the AG-519 drug. CNBC's Meg Tirrell reports.
Eli Lilly, in partnership with Express Scripts and Blink Health, plans to offer up to 40% discount on its insulin drugs. CNBC's Meg Tirrell reports.